A5008489174- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Screening and Detection
- Cancer Immunotherapy and Biomarkers
- Urologic and reproductive health conditions
- Nutrition and Health in Aging
- Inflammatory Biomarkers in Disease Prognosis
- Nutritional Studies and Diet
- Frailty in Older Adults
- MRI in cancer diagnosis
- Advanced X-ray and CT Imaging
- Multiple and Secondary Primary Cancers
- Infectious Disease Case Reports and Treatments
- Pediatric Urology and Nephrology Studies
- Testicular diseases and treatments
- Renal and Vascular Pathologies
- Urinary Bladder and Prostate Research
- Ultrasound and Hyperthermia Applications
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2025
IRCCS Humanitas Research Hospital
2020-2025
Humanitas University
2020-2025
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2025
The Netherlands Cancer Institute
2023-2025
The University of Texas MD Anderson Cancer Center
2022-2024
University of British Columbia
2023
Oxfam
2023
Liechtenstein Institute
2023
John Wiley & Sons (United States)
2023
Background: Robot-assisted partial nephrectomy (RAPN) is increasingly being employed in the management of renal cell carcinoma (RCC) and it expanding field complex tumors. The aim this systematic review was to consolidate assess results RAPN when dealing with entirely central hilar masses examine various methods used address surgical difficulties associated them. Methods: A thorough literature search September 2023 across databases focused on for masses, adhering PRISMA guidelines. primary...
A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate predictive power of mGPS oncological HG/G3 T1 NMIBC patients undergoing Bacillus Calmette-Guérin (BCG) therapy.We retrospectively reviewed patient's medical data from multicenter institutions. total 1382 with have been administered adjuvant intravesical BCG therapy, every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and...
Abstract Background Despite guideline recommendations, few institutions have implemented clinical pathways that incorporate frailty into routine decision‐making for patients undergoing radical cystectomy (RC). This paper presents an integrated pathway designed to address the needs of frail RC. The purpose study is determine whether a multifaceted prevention programme tailors interventions syndromic components can improve postoperative morbidity and recovery time patients. New insights will...
Objective To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort patients with high‐risk very‐high‐risk non‐muscle‐invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment. Materials Methods Data were retrospectively collected from 95 NMIBC, treated Gem/Doce at 12 centres between 2021 2024. Patients previously BCG who had completed full induction course received least one...
ABSTRACT Introduction We aim to critically assess Microultrasound (mUS) clinical performance in an outpatient setting, focusing on its ability reduce unnecessary diagnostic procedures, potentially reshape prostate cancer (PCa) protocols, and increase the rule out clinically significant (Gleason Score ≥ 3 + 4) PCa (csPCa). Materials Methods Between November 2018 April 2022, we conducted a prospective study involving men who underwent mUS examination due symptoms, PSA elevation, or...
Penile cancer is a rare but aggressive malignancy, with inguinal lymph node involvement representing key prognostic indicator (1, 2). NCCN guidelines recommend prophylactic dissection (ILND) for intermediate-to-high-risk patients (pT1b, ≥T2) non-palpable nodes, aiming early staging and improved outcomes (3). The SP-approach employs single incision advanced robotic instrumentation to enhance maneuverability, reduce morbidity, optimize recovery. Widely used in kidney prostate surgery (4, 5),...
683 Background: In 2021 we started an enhanced PCa screening in healthy Caucasian men with germline DNA repair pathogenic variants. Over 109 enrolled men, found two naïve patients bladder cancer (BC), but none PCa. This observation prompted us to investigate the prevalence of variants BC and suggest genetic counselling, testing for relatives subject BC. Methods: is a prospective ongoing study aiming detect, by exome analysis, (PV), likely (LPV) variant unknown significance (VUS) attending...
743 Background: Identifying optimal treatment strategies in nested bladder tumors is critical. This multicenter study aims at evaluating progression-free survival (PFS) end overall (OS) according to disease extent, presentation and including Bacillus Calmette-Guérin (BCG), radical cystectomy (RC) chemotherapy (CT). Methods: Data were collected from 61 patients with across 5 centers over a 10-year period (2013–2023). Patients stratified 1) time of diagnosis variant (disease onset Vs...
579 Background: Clear cell renal carcinoma (ccRCC) is characterized by a highly immunosuppressive tumor microenvironment that plays crucial role in promoting progression and conferring resistance to conventional treatments, such as chemotherapy radiotherapy. Systemic therapies, including tyrosine kinase inhibitors (TKIs) immune checkpoint (ICIs), have become central the management of ccRCC. However, patient responses these treatments vary significantly. Given pivotal ICIs ccRCC therapy,...
842 Background: Advanced Bladder Cancer (BC) presents significant challenges due to its high incidence and limited treatment options. Most patients initially present with non-muscle invasive bladder cancer (NMIBC), managed transurethral resection (TURBT) Bacillus Calmette–Guerin (BCG) therapy. However, some cancers recur or develop resistance, progressing muscle-invasive (MIBC), which is associated mortality curative While radical cystectomy (RC) the standard for MIBC, it has considerable...
849 Background: The growing interest in de-intensifying therapeutic strategies for low-grade bladder cancer (BC), including active surveillance (AS), highlights the imperative need precise patient stratification criteria. major clinical challenge is identification of patients at risk progression to high-grade disease. To address this unmet need, we investigated role germline pathogenic variants (PVs) and unknown significance (VUS) DNA repair genes (DRG) refine selection AS. Methods: This...
803 Background: The primary treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection (TUR), often followed by adjuvant intravesical therapies. Given the variable response to therapy, enhancing its efficacy critical reducing recurrence and progression MIBC. Recent studies have shown that MMC induces immunogenic cell death, suggesting potential in effectiveness of other therapies, such as BCG, activating acquired immunity. This study aimed evaluate safety neoadjuvant...
To assess the oncological outcomes of patients with high-risk (HR) and very (VHR) non-muscle-invasive bladder cancer (NMIBC) treated upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations from a contemporary European multicentre cohort. We conducted retrospective analysis 1491 diagnosed HR- or VHR-NMIBC database between 2015 2024. Patients were included if they received either RC at least five doses BCG. A 1:1 propensity score matching (PSM) according to clinically...